HLTH Forward Podcast – Details, episodes & analysis

In this episode, I sit down with Dr. Edgar Engleman, a pioneering Pathologist and physician-scientist at Stanford University whose work has shaped the very foundation of cancer immunotherapy. As we face rising global cancer rates, Dr. Engleman shares his insights into the evolving landscape of cancer research and what the numbers really mean—scientifically and socially.

We dive deep into his groundbreaking research on erythropoietin (EPO) and its surprising implications in cancer biology, as well as his continued innovations in using the immune system to fight tumors. Dr. Engleman also opens up about his involvement with vee-vo Capital and offers candid thoughts on the role of venture capital in bridging science and real-world impact.

No conversation about the future of medicine is complete without exploring AI. Dr. Engleman shares his perspective on how artificial intelligence is beginning to transform cancer detection and prediction, and how it might reshape diagnostics, treatment decisions, and even drug development.

But what strikes me most is Dr. Engleman’s enduring optimism—rooted in decades of scientific rigor. Despite the challenges, he remains steadfast in his belief that with a science-backed, collaborative approach, curing cancer is not just a dream—it’s a destination. This episode is a masterclass in science, hope, and what it means to pursue truth in medicine.

About

Dr. Edgar G. Engleman, MD, PhD, is a renowned pathologist and physician-scientist who serves as Professor of Pathology and of Medicine (Immunology & Rheumatology) at Stanford University School of Medicine. He received his BA magna cum laude from Harvard in 1967 and his MD from Columbia University in 1971. Following postdoctoral training in biochemistry at the NIH and immunogenetics at Stanford, he joined the Stanford faculty in 1978 and earned tenure in 1990. Dr. Engleman founded the Stanford Blood Center in 1980 and continues to serve as its Medical Director. He also co-directs the Tumor Immunology & Immunotherapy Program at the Stanford Cancer Institute and is affiliated with several interdisciplinary research centers, including Bio-X, the Diabetes Research Center, and the Neurosciences Institute.

Dr. Engleman’s research has made pioneering contributions to the field of cancer immunotherapy. His laboratory was the first to isolate and engineer dendritic cells to stimulate anti-tumor immune responses, work that led to the development of Sipuleucel-T (Provenge), the first FDA-approved active immunotherapy for cancer. His recent work focuses on reprogramming tumor-associated myeloid cells to trigger T-cell responses against cancer, with these approaches now in clinical trials. Beyond oncology, his research explores immune mechanisms in metabolic diseases, neurodegeneration, and transplantation, influencing innovative strategies like radiation-based tolerance induction. Dr. Engleman has mentored over 150 trainees, published more than 300 scientific papers, and teaches a popular course on tumor immunology at Stanford.

Support the show

In this compelling episode, I sit down with Matteo Franceschetti, the Italian-born Co-Founder and CEO of Eight Sleep, to explore how his journey from competitive ski racing to legal practice to clean-tech entrepreneurship led him to revolutionize the $500 million sleep optimization industry. Franceschetti shares his unique perspective on performance optimization, drawing powerful parallels between the recovery routines of elite athletes and the overlooked sleep needs of frontline healthcare workers. His company’s AI-powered platform is pushing boundaries by shifting the conversation from generic sleep hygiene to hyper-personalized, biometric-driven solutions designed for real-world impact.

As a healthcare technology expert, I’ve long witnessed the gaps in digital health solutions when it comes to addressing burnout and well-being at scale. What struck me in this conversation is Franceschetti’s bold assertion: sleep is not just a wellness perk, it is a foundational form of preventive care. In a field where clinicians are constantly on call, managing life-or-death decisions, and working under relentless pressure, sleep should not be optional—it should be engineered and protected like any other critical health asset.

We take a deeper dive into the data—statistics that are as concerning as they are compelling. One in three physicians report burnout. Healthcare workers sleeping less than seven hours per night face significantly higher rates of emotional exhaustion and clinical error. Franceschetti and I align on this point: the status quo isn’t just insufficient—it’s dangerous. Traditional wellness programs and sleep advice often ignore the deeply individualized nature of sleep, failing to account for how factors like genetics, shift work, stress hormones, and environmental disruption shape sleep architecture.

Eight Sleep’s approach is different. By leveraging real-time bio-signals—like heart rate variability, respiratory rate, and temperature—their platform continuously adapts to the sleeper’s unique physiology, effectively becoming a dynamic sleep coach embedded in your bed. This is the kind of precision health tool that healthcare has been missing.

From my vantage point in digital health innovation, Franceschetti’s work represents a promising shift toward preventive infrastructure rather than reactive treatment. As our system grapples with workforce shortages—only 70% of nurses remaining in practice, rising physician dropout rates—sleep tech could be a quiet but powerful lever. It’s not just about better rest; it’s about clinical accuracy, mental resilience, patient outcomes, and system-wide efficiency.

We close the conversation by exploring how sleep optimization could become a strategic pillar in the healthcare system of the future. Franceschetti argues—and I agree—that investing in personalized sleep technology could yield downstream benefits: fewer medical errors, improved staff retention, better patient satisfaction scores, and lower long-term care costs.

In an era where burnout threatens the very sustainability of care delivery, Eight Sleep’s technology isn’t just a consumer innovation—it’s a potential public health intervention.

About

Matteo Franceschetti is the Co-Founder and CEO of Eight Sleep, the sleep fitness company he established in 2014 in San Francisco. A native of Italy who was obsessed with performance from a young age as a competitive ski racer, tennis player, and car racer, Franceschetti transitioned from working in the top tier of the international legal world and founding two clean-tech companies before age 30 to revolutionizing sleep technology. Under his leadership, Eight Sleep has developed proprietary technology that uses cutting-edge AI and machine learning models to track bio signals during the night and o

Support the show

In a groundbreaking conversation, Wei Li, President of Omada Health, outlined a transformative vision for healthcare deeply rooted in a profound belief that health is a fundamental human right. Drawing inspiration from a World Health Organization quote that "help is the core of sustainable development," Li has dedicated his entire professional career to addressing the universal health challenges people face globally. His approach seamlessly integrates technology and human connection, focusing on comprehensive, personalized care across chronic conditions like diabetes, hypertension, and musculoskeletal issues. Li emphasizes that the real healthcare challenge lies not in medical appointments, but in the day-to-day struggles people face in implementing health changes, believing that health is the foundational element for achieving life's personal and professional objectives.

Central to Omada Health's strategy is a delicate balance between AI-driven solutions and human coaching, with Li asserting that human relationships remain the critical "currency" of behavior change. The company leverages billions of health data points to create highly personalized care experiences, particularly in innovative areas like GLP-1 medication management and behavioral intervention programs. By prioritizing accessibility, continuous support, and a holistic view of patient needs, Omada Health is fundamentally reimagining healthcare delivery—making it more integrated, proactive, and centered on individual patient experiences across diverse populations. Li envisions a future where healthcare becomes as accessible and routine as daily personal care, breaking down traditional barriers between in-person and virtual health services, and providing persistent, personalized support that recognizes the complex interplay of health challenges faced by patients.

About 

Wei Li is a global executive and leader with over 20 years of experience building and leading biopharmaceutical, diagnostic imaging, and digital health businesses across the world. After a rewarding 18-year career at Eli Lilly and Company, he came to Omada Health in 2019 to take on a new professional challenge––upending the status quo in chronic condition care by scaling virtual health. Currently, 70% of U.S. healthcare spending is for people with chronic conditions. He is steadfast in his belief that Omada is at the forefront of health tech innovation that's gradually improving outcomes and reducing costs for health systems and organizations.

He holds dual Bachelor of Science degrees in biochemistry and molecular biology from the University of Wisconsin-Madison and a Master of Business Administration from the Kelley School of Business, Indiana University. Over the course of his career, he has demonstrated an ability to grow successful organizations, lead turn-arounds, and establish start-ups. He has brought his wealth of experience to Omada, where he has surrounded himself with amazing people, built a strong team, set high expectations, and helped create an organization grounded in values and principles.

In addition to his professional achievements, Li has published a children's book, "Anny The Tall Girl," a touching story imbued with diversity, equity, and inclusion. He and his wife Sarah are the proud parents of two daughters.

Support the show

Medtronic's technological strategy represents a sophisticated convergence of AI, data analytics, and medical innovation, positioned to fundamentally reshape healthcare delivery. Under Chief Technology Officer Ken Washington's leadership, the organization is pioneering a model of technological augmentation that prioritizes human expertise while leveraging advanced computational capabilities. The core strategic approach focuses on developing intelligent medical devices that provide precision insights and predictive healthcare interventions.

The technology framework centers on comprehensive data infrastructure, spanning 70 distinct medical conditions. By meticulously collecting and analyzing patient data through advanced sensing technologies, Medtronic is developing AI-enabled platforms capable of personalized health monitoring and preemptive diagnostic capabilities. This approach transforms medical technology from a reactive to a predictive model, potentially reducing healthcare costs and improving patient outcomes through early intervention strategies.

Washington's innovation model extends beyond technological development to include critical considerations of regulatory compliance, global scalability, and sustainable design. With a commitment to net-zero emissions by 2045 and strategic partnerships across healthcare and technology sectors, Medtronic is positioning itself as a leader in responsible, forward-thinking medical innovation. The organization's approach integrates high-precision robotics, advanced algorithmic models, and data-driven personalization to create transformative healthcare solutions that address complex global health challenges.

About
Ken Washington serves as Senior Vice President and Chief Technology and Innovation Officer. In this role, Ken is responsible for accelerating Medtronic innovation through product development and technology strategies.

Ken joined Medtronic in 2023 and brought with him deep expertise in leading technology development and execution across industries including robotics, consumer products, automotive, and space. Ken inspires teams and pushes them even further in their ability to invent, innovate and create positive market disruptions. He partners closely with teams and leaders around Medtronic to ensure our products and therapies continue to advance the Mission to better serve patients and customers.

Prior to joining Medtronic, Ken was Vice President and General Manager of Consumer Robotics at Amazon. Prior to that, he was Chief Technology Officer at Ford Motor Company, overseeing development of the company’s technology strategy including next-generation vehicle architectures, controls and automated systems. He also spent seven years at Lockheed Martin in various leadership roles including Chief Technology Officer, Chief Privacy Officer and Vice President, Advanced Technology Center, Lockheed Martin Space Systems Company.

Ken is an internationally recognized thought leader on technology and innovation. He earned a Bachelor of Science, a Master of Science, and a PhD in nuclear engineering from Texas A&M University. He was inducted into the National Academy of Engineering in 2020 and was inducted into the Black Engineer Hall of Fame in 2023.

Support the show

• 95% of rare diseases do not have approved treatments, highlighting the significant unmet need in the rare disease community.
• The unpredictable symptoms and long diagnostic process for conditions like neuromyelitis optica spectrum disorder (NMOSD) can lead to debilitating long-term disabilities.
• There is an urgent need for increased education, resources, and support to address the global diagnostic challenge and financial burden on rare disease patients and their families.

Tamar shares her inspiring healthcare journey, starting as a provider and then transitioning to the life sciences industry after marrying an Air Force member and moving to North Dakota. She now advocates for the rare disease community, particularly focusing on NMOSD, a rare autoimmune disorder that affects the central nervous system. Tamar explains that while there are an estimated 7,000-10,000 rare diseases, only 5% have approved treatments, and 90% of these diseases do not have any approved treatments

The symptoms of NMOSD can be unpredictable and lead to long-term disabilities like vision loss and paralysis. Tamar emphasizes that the journey to diagnosis for rare disease patients can be long, often taking 7 years on average, and that NMOSD is more common in women in their mid-30s, though it can also affect men and children. Tamar discusses the challenges in diagnosing rare diseases like neuromyelitis optica spectrum disorder (NMOSD)

Rare diseases are often genetic in nature, making diagnosis difficult as symptoms can be ambiguous. Tamar highlights Alexion's history of pioneering research and development in the rare disease space, including complement-based therapies and the promise of cell and gene therapies. She emphasizes the global nature of the diagnostic challenge, with patients often seeing multiple specialists before receiving the correct diagnosis

Tamar highlights the significant financial burden on families dealing with rare diseases, with costs 10-20 times higher annually. She also touches on the promise of advancing technologies, like genome sequencing, to help with earlier diagnosis, but emphasize that access and affordability remain challenges. Overall, the discussion sheds light on the struggles faced by those impacted by rare diseases and the need for more education, resources, and support for patients and their caregivers

The discussion highlights the significant challenges faced by rare disease patients and their families, including the high financial burden and lack of awareness and support. There is a need for increased education, policy changes, and investment to foster rare disease diagnosis, treatment, and access to care. 

We share the call for urgent action to address these issues and prepare for the future, given the aging population and the potential for a "silent epidemic" if left unaddressed. We discuss the challenges of diagnosing rare diseases, emphasizing the need for greater education and awareness among medical professionals. 

Support the show

In this episode I sit down with a good friend and mentor Rob Fried, CEO of ChromaDex, who shares his remarkable transition from Hollywood executive producer to leader of a cutting-edge nutraceutical company. Fried's journey from producing films like Rudy and Godzilla to helming a science-focused organization dedicated to extending human healthspan showcases the power of reinvention and following one's passion.

Through ChromaDex's pioneering research into NAD+ and cellular health, Fried has positioned himself at the intersection of scientific innovation and consumer wellness, bringing Hollywood storytelling skills to communicate complex scientific concepts to a broader audience.

The conversation delves deep into the crucial role of NAD+ in cellular health, particularly its impact on mitochondrial function – our cells' power plants. As Fried explains, our NAD+ levels naturally decline with age, accelerated by modern lifestyle factors like poor sleep, excessive alcohol consumption, and environmental stressors. We explore the growing need for consumer education in the supplement industry and draw compelling parallels between the responsible AI movement and the necessity for ethical governance in the supplement space. Fried advocates for establishing a responsible supplement board to ensure product quality, ingredient sourcing transparency, and consumer safety – addressing the current regulatory gaps in the industry.

Buy Here- Upgrade your cellular Health 

About NAD+
NAD+ (Nicotinamide Adenine Dinucleotide) serves as a fundamental molecule in cellular health, playing multiple vital roles throughout the body. At its core, NAD+ is essential for energy production, working within our mitochondria to convert food into usable cellular energy. Beyond energy production, it acts as a crucial coenzyme for hundreds of biological processes, including DNA repair, gene expression regulation, and cellular stress response. NAD+ activates important proteins called sirtuins, which are often referred to as "longevity genes" due to their role in promoting healthy aging and cellular maintenance. As we age, our natural NAD+ levels decline, potentially contributing to various age-related conditions and decreased cellular function. This decline affects multiple aspects of health, including cognitive function, muscle strength, metabolic health, and cardiovascular wellness. Research has shown that maintaining healthy NAD+ levels can support improved energy levels, enhanced cellular repair, better brain function, stronger immune response, and more efficient metabolism. The molecule's influence extends to supporting liver health, promoting muscle recovery after exercise, regulating circadian rhythms, and potentially protecting against various age-related diseases, making it a crucial target for research in healthy aging and longevity science.

About Rob Fried
Robert Fried is the Chief Executive Officer (CEO) of ChromaDex. Mr. Fried is an Academy Award and Emmy Award-winning motion picture producer.  He has held senior roles at entertainment companies Savoy Pictures (CEO), Columbia Pictures (Executive Vice President), and Fried Films (founder, CEO).  He has also founded and served as CEO of internet companies Feeln (now Hallmark Movies Now), WHN (a leading e-commerce service provider), and Healthspan Research (now part of ChromaDex). Mr. Fried holds a B.S. from Cornell University and an M.B.A. from the Columbia University Graduate School of Business.

Support the show

In this episode I am in conversation with Matthew Holt, a prominent figure in health technology and policy;  an uncensored discussion on the current state of healthcare. Known for his frank and often controversial opinions, Holt is expected to delve into pressing issues such as the impact of artificial intelligence on medical practices, the ongoing challenges of healthcare affordability, and the slow pace of digital transformation in the industry. We'll explore his views on why many promised healthcare innovations have failed to deliver and what he believes are the most promising solutions on the horizon.

The interview will also touch on sensitive topics that often go undiscussed in mainstream healthcare conversations. Holt may share his unfiltered thoughts on the influence of big pharma and insurance companies, the shortcomings of current health policies, and the real-world consequences of a fragmented healthcare system.

About
Matthew Holt is the founder and publisher of The Health Care Blog and still writes regularly for the site and hosts the #THCBGang and #HealthInTwoPoint00 video shows/podcasts. He was co-founder of the Health 2.0 Conference and now also does advisory work mostly for health tech startups at his consulting firm SMACK.health.

Support the show

I had the privilege of sitting down with Interwell Health's CEO, Robert Sepucha to explore the future of kidney care in America. The statistics are sobering - chronic kidney disease impacts an estimated 37 million U.S. adults, with over 500,000 relying on dialysis. As I listened to Bobby's insights, it became clear that innovative care models aren't just desirable but crucial. Interwell Health is tackling this challenge head-on, and I was fascinated to learn about its value-based approach. Their mission to improve patient outcomes while simultaneously reducing the enormous $114 billion annual Medicare spending on kidney disease is both ambitious and inspiring.

Our discussion deeply explored what makes Interwell unique. The merger of Fresenius Health Partners, Cricket Health, and Interwell Health has created a powerhouse in kidney care, and I was eager to understand how this combination translates to better patient care. Bobby's explanation of their integrated care model was eye-opening. 

By marrying Acumen EHR's sophisticated data analytics with hands-on nephrology expertise, they're reimagining the entire patient care journey. What struck me most was how this approach extends beyond just managing the disease - it's about empowering patients, particularly through increased access to home-based care options

About
As Chief Executive Officer, Bobby leads Interwell Health’s overall strategy and is passionate about helping patients live their best lives while delivering results for payers and providers. Bobby brings over ten years of value-based kidney care experience to his role, having served as CEO of Cricket Health and as a senior executive in policy and corporate affairs at Fresenius Medical Care. He has long worked at the intersection of business, policy, and law, having served as chief of staff to a member of Congress and General Counsel at the Massachusetts Life Sciences Center. He also practiced as an attorney with Gunderson Dettmer in Silicon Valley and Boston where he represented venture capital firms and high-tech startups. Bobby received a Juris Doctor degree from the University of Michigan and a BA degree from Dartmouth College.

Support the show

In this episode, I am in conversation with Viz.AI CEO, Dr. Chris Mansi, a pioneer in leveraging artificial intelligence for early disease detection. Our discourse unveiled the revolutionary strides Viz.ai has made in the medical field, particularly in neurovascular and cardiology domains. Dr. Mansi elucidated how their AI-powered platform has dramatically reduced time-to-treatment for stroke patients, citing their flagship product that can detect large vessel occlusions in CT scans within minutes, enabling rapid triage and intervention.

Their AI algorithms have shown remarkable efficacy in detecting pulmonary embolisms and aortic dissections, conditions where timely diagnosis can mean the difference between life and death. Dr. Mansi shared a poignant case study where their AI platform identified a subtle aortic abnormality that human radiologists had initially overlooked, potentially averting a catastrophic outcome.

In the United States alone, it's estimated that diagnostic errors contribute to 40,000 to 80,000 deaths annually. Furthermore, approximately 12 million adults annually experience diagnostic errors in outpatient settings. 

Chris emphasized that their AI tools are not meant to replace human expertise but to augment it, creating a synergy that promises to revolutionize patient outcomes. By providing rapid, accurate medical imaging analyses, Viz.aAI's technology empowers healthcare providers to make swift, informed decisions, potentially saving thousands of lives each year. This harmonious blend of artificial intelligence and human insight represents a new frontier in medicine, where the early detection of diseases becomes a possibility and a standard of care.

About 
Viz.ai, Inc. is emerging as the leader in applied artificial intelligence in healthcare. Our mission is to fundamentally improve how healthcare is delivered in the world, through intelligent software that promises to reduce time to treatment and improve access to care. Our flagship product, Viz LVO, leverages advanced deep learning to communicate time-sensitive information about stroke patients straight to a specialist who can intervene and treat. In February 2018, the U.S. Food and Drug Administration (FDA) granted a de novo clearance for Viz LVO, the first-ever computer-aided triage and notification platform. Most recently, Viz.ai announced its second FDA clearance for Viz CTP through the 510(k) pathway, offering healthcare providers an important tool for automated cerebral image analysis.

Support the show

In this episode, we explore the groundbreaking fusion of virtual reality and mental health with Nanea Reeves, the innovative CEO and founder of TRIPP. With nearly 1 in 5 adults in the U.S. experiencing mental illness each year, and global depression rates rising by 28% since 2020, the need for novel therapeutic approaches has never been more urgent. Nanea's journey into this space isn't merely a business venture; it's a deeply personal mission rooted in her experiences and an unwavering commitment to improving lives.

We'll delve into how TRIPP leverages the immersive power of VR to revolutionize mindfulness and emotional well-being. Our discussion will address a fascinating paradox: while some view VR as a potential escapism, it's proving to be a powerful tool for confronting and managing mental health challenges. For instance, we'll explore how veterans, who often struggle with PTSD, find unexpected comfort in interacting with avatars rather than humans, free from the fear of judgment.

Our conversation will navigate the unique hurdles of developing mental health technology, VR's potential to democratize access to wellness practices, and the delicate balance of harnessing technology while mitigating concerns about digital overwhelm. Nanea's insights will offer listeners a glimpse into a future where cutting-edge technology and compassionate, human-centered design converge to transform mental health care.

About
Nanea Reeves founded TRIPP, an award-winning global XR Wellness company, following a tremendous personal loss that led her to rethink her life’s purpose. With a lifelong meditation practice that began in her teens, Nanea recognized its transformative powers, and she wanted to figure out a way to make meditation more accessible to people around the world. TRIPP was the solution, which married her meditation practice with her love of video games and her extensive software development experience. Through interactive, immersive experiences that combine gameplay mechanics, mindfulness structures, and psychedelic-inspired environments, users are guided into powerful, awe-inspiring, transformative states. Ultimately, TRIPP aims to empower people to take control of their mental and emotional well-being wherever they are.

Nanea brings over 15 years of experience in digital distribution, video game technologies, and mobile application development. Before co-founding TRIPP, Nanea was President and COO of textPlus, one of the top mobile communications applications. Nanea was also COO at Machinima, the largest gaming network on YouTube that was acquired by Warner Brothers, Chief Strategy Officer at Gakai (acquired by Sony) and she was the Senior Vice President and COO of Global Online at Electronic Arts who acquired JAMDAT, the mobile game start-up that Nanea ran technology at. Through her leadership at these previous companies, she’s facilitated $1.6 billion in exits.

Support the show